vs
Side-by-side financial comparison of Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Qudian Inc. (HTT). Click either name above to swap in a different company.
Corbus Pharmaceuticals Holdings, Inc. is the larger business by last-quarter revenue ($1.2M vs $1.1M, roughly 1.1× Qudian Inc.). Qudian Inc. runs the higher net margin — 239.8% vs -1159.2%, a 1399.0% gap on every dollar of revenue.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel targeted therapies for rare, serious inflammatory, fibrotic and immune-mediated diseases. It primarily operates across North America and other developed markets, addressing high unmet medical needs for underserved patient populations.
Qudian Inc. is a China-based fintech service provider that mainly offers small consumer credit solutions, risk management technical services, and related digital financial products. Its core target users are young mass consumers across China, with all key business operations focused on the domestic Chinese market.
CRBP vs HTT — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.1M |
| Net Profit | $-13.8M | $2.6M |
| Gross Margin | — | 11.1% |
| Operating Margin | -1304.0% | -121.7% |
| Net Margin | -1159.2% | 239.8% |
| Revenue YoY | 447.9% | — |
| Net Profit YoY | -37.1% | — |
| EPS (diluted) | $-1.15 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 24 | $1.2M | $1.1M | ||
| Q2 24 | $906.0K | $1.0M | ||
| Q1 24 | $-177.0K | $1.1M | ||
| Q3 23 | — | $559.9K | ||
| Q4 22 | $-641.0K | — | ||
| Q3 22 | $0 | $2.1M | ||
| Q2 22 | $-490.3K | $2.2M | ||
| Q1 22 | $0 | $4.4M |
| Q3 24 | $-13.8M | $2.6M | ||
| Q2 24 | $-10.0M | $1.9M | ||
| Q1 24 | $-6.9M | $-1.4M | ||
| Q3 23 | — | $-3.4M | ||
| Q4 22 | $-10.9M | — | ||
| Q3 22 | $-8.8M | $-12.6M | ||
| Q2 22 | $-13.2M | $-1.3M | ||
| Q1 22 | $-9.4M | $-3.1M |
| Q3 24 | — | 11.1% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 61.0% | ||
| Q1 22 | — | 84.1% |
| Q3 24 | -1304.0% | -121.7% | ||
| Q2 24 | -1212.8% | -107.6% | ||
| Q1 24 | 5436.3% | -129.9% | ||
| Q3 23 | — | -340.6% | ||
| Q4 22 | 1684.5% | — | ||
| Q3 22 | — | -272.1% | ||
| Q2 22 | 2516.6% | -27.8% | ||
| Q1 22 | — | -32.9% |
| Q3 24 | -1159.2% | 239.8% | ||
| Q2 24 | -1103.4% | 187.1% | ||
| Q1 24 | 3897.4% | -131.8% | ||
| Q3 23 | — | -612.3% | ||
| Q4 22 | 1697.3% | — | ||
| Q3 22 | — | -588.2% | ||
| Q2 22 | 2702.0% | -58.1% | ||
| Q1 22 | — | -70.8% |
| Q3 24 | $-1.15 | $0.01 | ||
| Q2 24 | $-0.90 | $0.01 | ||
| Q1 24 | $-0.83 | $-0.01 | ||
| Q3 23 | — | $-0.02 | ||
| Q4 22 | $-2.60 | — | ||
| Q3 22 | $-2.11 | $-0.05 | ||
| Q2 22 | $-3.18 | $-0.01 | ||
| Q1 22 | $-2.26 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.4M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $150.5M | $225.2M |
| Total Assets | $164.2M | $246.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $159.4M | $104.9M | ||
| Q2 24 | $147.0M | $112.8M | ||
| Q1 24 | $120.1M | $140.6M | ||
| Q3 23 | — | $183.4M | ||
| Q4 22 | $59.2M | — | ||
| Q3 22 | $66.2M | $154.1M | ||
| Q2 22 | $73.3M | $168.3M | ||
| Q1 22 | $86.1M | $180.3M |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q4 22 | $21.6M | — | ||
| Q3 22 | $21.2M | — | ||
| Q2 22 | $21.2M | $521.5K | ||
| Q1 22 | $21.2M | — |
| Q3 24 | $150.5M | $225.2M | ||
| Q2 24 | $125.5M | $217.5M | ||
| Q1 24 | $97.0M | $218.9M | ||
| Q3 23 | — | $226.0M | ||
| Q4 22 | $33.0M | — | ||
| Q3 22 | $41.9M | $225.5M | ||
| Q2 22 | $49.5M | $253.0M | ||
| Q1 22 | $61.2M | $269.4M |
| Q3 24 | $164.2M | $246.8M | ||
| Q2 24 | $152.0M | $227.9M | ||
| Q1 24 | $125.7M | $234.9M | ||
| Q3 23 | — | $239.4M | ||
| Q4 22 | $66.3M | — | ||
| Q3 22 | $73.8M | $249.6M | ||
| Q2 22 | $82.1M | $283.4M | ||
| Q1 22 | $95.7M | $296.3M |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q4 22 | 0.65× | — | ||
| Q3 22 | 0.51× | — | ||
| Q2 22 | 0.43× | 0.00× | ||
| Q1 22 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $-13.9M | — | ||
| Q2 24 | $-8.9M | — | ||
| Q1 24 | $-8.0M | — | ||
| Q3 23 | — | — | ||
| Q4 22 | $-7.5M | — | ||
| Q3 22 | $-7.2M | — | ||
| Q2 22 | $-12.2M | — | ||
| Q1 22 | $-10.6M | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | $-10.6M | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q4 22 | 0.0% | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 0.0% | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
